Provectus Disappears 'Breakthrough' Drug Claim on Web Site

Did you notice the big change on the home page of Provectus Biopharmaceuticals' (PVCT) web site today?

Here's a screen shot of the site today. PV-10 is referred to as an "Investigational Drug for Cancer."



No big deal? Well, take a look at what Provectus' web site looked like yesterday:






PV-10 is a "Breakthrough Cancer Drug"? Really? That's news to all of us, given Provectus is supposed to hear back from the FDA this week about the request to grant PV-10 Breakthrough Therapy status for skin cancer. So far, Provectus has said nothing about the FDA's response. 

If Provectus hasn't heard from FDA yet on PV-10's "Breakthrough" status, why describe the drug on the home page of its web site as a "Breakthrough Cancer Drug"? Today, PV-10 is merely an "Investigational Drug." Maybe someone at the FDA caught a glance at Provectus' web site and slapped a wrist. We all know Provectus would never try to fool investors. Nah, this fine, upstanding company would never do something sneaky like tricking people into thinking PV-10 was granted Breakthrough Therapy status when it wasn't.


Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

If you liked this article you might like

This Drug Company Loaned Its Now-Fired CEO $2.5M for Made-Up Travel 'Advances'

This Drug Company Loaned Its Now-Fired CEO $2.5M for Made-Up Travel 'Advances'

5 Breakout Stocks Under $10 Set to Soar

5 Breakout Stocks Under $10 Set to Soar

Provectus Admits Cash Running Low, Financing Coming Soon

Provectus Admits Cash Running Low, Financing Coming Soon

Biotech Stock Mailbag: Vanda, Navidea, Provectus

Biotech Stock Mailbag: Vanda, Navidea, Provectus

Biotech Stock Hate Mailbag: The Hostile React-o-Meter Meltdown Edition

Biotech Stock Hate Mailbag: The Hostile React-o-Meter Meltdown Edition